Mr. Lewis “Lew” Shuster

e-mail:  info@Shustercapital.com

Mr. Shuster is presently CEO of Shuster Capital, a strategic and operating advisor to life science company executives and investors with a focus on contract services, lab reagents and instruments, clinical diagnostics,  and selected medical devices.

Life Science Business Transitions

Emerging Rapid Growth---Turnarounds

Education:

Stanford University Graduate School of Business (1979-1981)

    MBA degree, June 1981. Arjay Miller Scholar (top 10% of class).

Swarthmore College (1973-1977)

    BA degree with HIgh Honors, May 1977. Major in Economics. Phi Beta Kappa. Part-time and summer computer programming consultant.

Areas of Expertise:

1. •    Strategic advisory: Cypress Bio. (formerly NASDAQ: CYPB) (diagnostics), Epitomics (reagents, diagnostics, services), Phalanx (reagents, services), Epocal (diagnostics), Singulex (diagnostics, instruments/reagents), Wafergen (instruments/reagents)
   

2. •    Due diligence and investor advisory: (Client venture and hedge funds and companies evaluated not disclosed due to confidentiality.)
   

3. •    Turnarounds: Legacy Pharm. (services), Aviva Systems Biology (reagents), Life Therapeutics (blood products--ASX:LFE), (see also full time positions below)
   

4. •    Start-ups: Retrotope (therapeutics), Sorrento Therapeutics (therapeutics), Aztechnology (reagents), Intrinsic MetaBio (diagnostics)
   

(for more see the areas of expertise page and boards of directors)